170 related articles for article (PubMed ID: 19687322)
1. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
[No Abstract] [Full Text] [Related]
2. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Ewer MS; Tan-Chiu E
J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
[No Abstract] [Full Text] [Related]
3. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab versus lapatinib: the cardiac side of the story.
Azim H; Azim HA; Escudier B
Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab cardio-oncology: lessons learned.
Frankel C
Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
[TBL] [Abstract][Full Text] [Related]
6. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
8. Trastuzumab-associated cardiotoxicity.
Keefe DL
Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
[TBL] [Abstract][Full Text] [Related]
9. Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still ongoing.
Magné N; Védrine L; Chargari C
J Clin Oncol; 2009 Dec; 27(34):e239; author reply e240-1. PubMed ID: 19884526
[No Abstract] [Full Text] [Related]
10. [Cardiac dysfunction induced by trastuzumab].
Campone M; Bourbouloux E; Fumoleau P
Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
[TBL] [Abstract][Full Text] [Related]
11. Cardiac issues related to trastuzumab.
Perez EA
Breast; 2004 Jun; 13(3):171-2. PubMed ID: 15177417
[No Abstract] [Full Text] [Related]
12. Learn to assess for and manage trastuzumab-induced cardiotoxicity.
Becze E
ONS Connect; 2009 Dec; 24(12):12-3. PubMed ID: 20039567
[No Abstract] [Full Text] [Related]
13. Trastuzumab in breast cancer.
Gilbert SG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
[No Abstract] [Full Text] [Related]
14. Cardiac risks in multimodal breast cancer treatment.
Budach W
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
[No Abstract] [Full Text] [Related]
15. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J
Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689
[TBL] [Abstract][Full Text] [Related]
16. Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.
Morris PG; Hudis CA
Breast Cancer Res Treat; 2011 Jun; 127(2):585-6. PubMed ID: 18791822
[No Abstract] [Full Text] [Related]
17. Blocking breast cancer relapses.
Johns Hopkins Med Lett Health After 50; 2006 Feb; 17(12):1-2. PubMed ID: 17115471
[No Abstract] [Full Text] [Related]
18. Trastuzumab--mechanism of action and use.
Mir O; Berveiller P; Pons G
N Engl J Med; 2007 Oct; 357(16):1664-5; author reply 1665-6. PubMed ID: 17948347
[No Abstract] [Full Text] [Related]
19. Brain metastases in patients receiving trastuzumab for breast cancer.
Salmaggi A; Silvani A; Boiardi A
Neurol Sci; 2007 Mar; 28(1):1. PubMed ID: 17385088
[No Abstract] [Full Text] [Related]
20. Trastuzumab.
Nurs Times; 2006 Mar 7-13; 102(10):33. PubMed ID: 16548266
[No Abstract] [Full Text] [Related]
[Next] [New Search]
